Jacquelyn A Hank

5PUBLICATIONS
32CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Haematological tumoursImmunogenetics (incl. genetic immunology)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Jul 15, 2022
Outcomes Following GD2-Directed Postconsolidation Therapy for Neuroblastoma After Cessation of Random Assignment on ANBL0032: A Report From the Children's Oncology Group.

Ami V Desai, Andrew L Gilman, Mehmet Fevzi Ozkaynak

|Dec 06, 2021
Improved Outcome in Children With Newly Diagnosed High-Risk Neuroblastoma Treated With Chemoimmunotherapy: Updated Results of a Phase II Study Using hu14.18K322A.

Wayne L Furman, Beth McCarville, Barry L Shulkin

|Jan 28, 2021
Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032.

Alice L Yu, Andrew L Gilman, M Fevzi Ozkaynak

|Jul 10, 2020
A Phase 1 and pharmacokinetic study evaluating daily or weekly schedules of the humanized anti-GD2 antibody hu14.18K322A in recurrent/refractory solid tumors.

Michael W Bishop, Paul R Hutson, Jacquelyn A Hank

|Mar 11, 2020
Outcome-Related Signatures Identified by Whole Transcriptome Sequencing of Resectable Stage III/IV Melanoma Evaluated after Starting Hu14.18-IL2.

Richard K Yang, Igor B Kuznetsov, Erik A Ranheim

Pageof 1

Frequent Collaborators

3 joint publications

Barry L Shulkin

3 joint publications

Paul M Sondel

3 joint publications

Alice Yu

2 joint publications

John M Maris